Zepbound, obstructive sleep apnea and FDA

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...